A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Dasatinib (PHYRAGO)

Dasatinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

First FDA approval2006-06-27
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$850.6M in CY2024 Part D spend75K claims · 16K beneficiaries · 329 plans surveyed

Lowest NADAC
$29.19/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$85.37
Across all dosage forms in distribution.
Highest NADAC
$590.98
Wide spread — brand-strength NDCs still in market.
Plans with PA
1992 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Dasatinib used for?

Dasatinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

Is there a generic for Dasatinib?

Yes. 48 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Dasatinib?

Across 329 Part D plans, Dasatinib averages $85.37/unit (NADAC). Lowest available: $29.19/unit. Highest in distribution: $590.98/unit.

Is Dasatinib on the FDA shortage list?

No. Dasatinib is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Kinase Inhibitor6 alternatives in D1
01
Everolimus
Brand: Afinitor
$2.29Lowest NADAC
10Generic mfrs
$259.1MCY24 Part D spend
Compare →
02
Imatinib
Brand: Gleevec
$0.827Lowest NADAC
12Generic mfrs
$318.0MCY24 Part D spend
Compare →
03
Everolimus Tablets
Brand: Everolimus
$2.29Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Ruxolitinib
Brand: JAKAFI
$34.14Lowest NADAC
0Generic mfrs
$3.38BCY24 Part D spend
Compare →
05
Sunitinib Malate
Brand: SUTENT
Lowest NADAC
8Generic mfrs
$69.0MCY24 Part D spend
Compare →
06
Erlotinib
Brand: Erlotinib
Lowest NADAC
8Generic mfrs
$9.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.